estim lower post io model updat nearer term nektar
collabor still forecast opdivo lead although lead
narrow offer among best growth prospect howev pend
clariti nsclc landscap view share fairli valu current level
opdivo estim well consensu part factor
adjuv set kol think key driver io time howev
updat model reflect number factor impact io
compani other specif clip opdivo forecast
vs consensu vs consensu
new assumpt detail cowen
number assum rhhbi garner equal share nsclc
pend clariti combo studi slower previous forecast sale evolut
ou market io overal delay anvil nci-sponsor adjuv lung trial
hope would put opdivo adjuv lung map full potenti
tmb tap success work suggest alreadi
achiev os via endpoint ad uncertainti delay year
estim ep vs guidanc prior
dilut consensu prior estim ep forecast
reflect dilut vs consensu prior estim
vs previous ep compound-annual-growth-rate
sale forecast vs guidanc low mid singl digit prior estimate
vs prior estimate estim
forecast vs previous impli sale compound-annual-growth-rate
forecast pegyl sale
record incom factor gpm
profit split associ estim
peak reflect collabor exclus
period financ cost collabor up-front payment modest
impact estim lead rhhbi
two molecul target similar
seen clinic data roch molecul
pleas see page report import disclosur
long-standing view combin opdivo plu yervoy disrupt potenti
io unchang howev increas visibl competitor strategi data add
risk opdivo sale ep prospect intermedi term take-over remain
opdivo yervoy os data
nsclc late
opdivo yervoy approv rcc
opdivo approv dose
better-than-expect data/sal
opdivo io target
competitor gain sale disappoint
bristol-my squibb compani global biopharmaceut compani lead product
cardiovascular oncolog diabet area among other compani strong
pipelin includ sever product sizabl market potenti
compani data cowen compani estim
cowen compani
cowen compani
cowen compani
cowen compani
commentsanti-infect baraclud gener launch market eu japan share gener china impact brand gener eubaraclud entecavir hepat hepat non-nuc inhibitor approv japan daklinza/sunvepra develop asunaprevir hepat approv japan china pursu eu daclatasvir hepat patient approv japan eu chinareyataz share patent expir teva launch patent expir atazanavir once-daili proteas inhibitorazactam monobactam right sold duraatripla/sustiva franchis sustiva patent exp use patent exp settlement delay competit clipsatripla/sustiva franchis eu patent expir franchis sustiva portion sustiva/truvada qd gilead royalti inj broad spect cefepim right sold hiv ec domin gener competit barr top aminoglycosid certain right broad spectrum/dos regimen patent expir bulk penicillin mostli intern otheranti-infect approv tumor type futur differenti key nivo/ipi novel combo adjuv useopdivo lower given slower penetr io overal adjuvantopdivo nivolumab antibodi numer datapoint upcom includ adjuv readoutsorencia phase lupu nephriti substanc patent exp method use patent exp earli iv/sq substanc pat exp method myl/momenta biosimilar clinic fail iv/sq abatacept approv rheumatoid arthrit psasprycel share pat exp litig settl apotex allow launch gleevec gener like temper growthsprycel patent exp revok pto appeal hear gleevec gener like temper growthsprycel src/abl kinas inhib resist cml gi lung stromal readi trial prostat meet endpointyervoy near term pressur monotherapi melanoma futur key nivo comboyervoy ipilimumab monoclon ab melanoma tumor immun oncolog combin use drive elotuzumab approv refractori multipl myeloma line data anti-kir io target biolog phase io target biolog phase io target biolog phase small molecul io target phase immunosci psoriasi small molecul phase iibtk immunosci small molecul phase lysophospholipid receptor antagonist signal tx idiopath pulmonari fibrosi phase ii small manag fibrot diseas biolog phase idiopath pulmonari fibrosi myelofibrosi phase ii biolog psa-target cancer io tx mcrpc phase bavarian uracil tegafur leucovorin colon cancer foreign market cowen
cowen compani
commentscancer/immunolog continuednulojix belatacept block t-cell activ market renal transplant reject lslet transplant phase gener pressur foreign better toxic profil platinol genericsvepesid patent expir phosphat patent expir licens miscellan product genericscanc approv spaf dvt treatment prophylaxi market share patent expir approv spaf dvt treatment prophylaxi patent expir apixaban oral factor xa inhibitor pfizerrecothromnmnm right purchas medicin compani close patent expir xia small molecul cardiovascular small molecul phase iinitroxyl heart failur small molecul phase anticoagul gener competit clipsquestran older resin cholesterol reduc over-the-counter outlook unclearplavix exclus end pediatr extensionplavix gener euplavix patent expir patent expir canada mexico argentina avapro arb gener productscardiova cowen
cowen compani
 reflect upsa line effect older squibb productsabilifi total revenu agreement expir abilifi total revenu agreement expir eu canadaabilifi total revenu schizophrenia miscellan product genericscn potenti over-the-counter switch older product neg sale suggest heavi discountsderm gener exclus end pediatr extensionglucophag exclus end expect declin expir royalti allianc agreementstot industri averag growth clip fervex cold flu prep eu total over-the-counter /canadian franchis sold novarti retain certain intern market new pharmaceut drive growth cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl eliqui orencia
sprycel baraclud success pipelin product especi nivolumab success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
